title: Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?
abstract: Current marketed antiepileptic drugs (AEDs) consist of a variety of structural classes with different mechanisms of action. These agents typically have non-overlapping efficacy and side-effect profiles presenting multiple treatment options for the patient population. However, approximately 30% of seizure sufferers fail to respond to current therapies often because poorly tolerated side-effects limit adequate dosing. The scope of this review is to summarize selected advances in 2ndand 3rdgeneration AEDs as well as compounds in development with novel mechanisms of action.
authors.affiliation: Icagen, Inc., 4222 Emperor Blvd, Durham, NC 27703, USA. agerlach@icagen.com.
authors.forename: Aaron C
authors.initials: AC
authors.lastname: Gerlach
authors.affiliation: Icagen, Inc., 4222 Emperor Blvd, Durham, NC 27703, USA. jkrajewski@icagen.com.
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Krajewski
keywords: AED; anticonvulsant; antiepileptic; epilepsy; seizure